Cargando…

Two-dimensional ultrathin Ti(3)C(2) MXene nanosheets coated intraocular lens for synergistic photothermal and NIR-controllable rapamycin releasing therapy against posterior capsule opacification

Posterior capsule opacification (PCO) is one of the most frequent late-onset complications after cataract surgery. Several kinds of drug-eluting intraocular lenses (IOL) were designed for sustainable drug release to suppress ocular inflammation, the proliferation of lens epithelial cells (LECs) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Zi, Huang, Yang, Li, Jinglan, Ma, Tianju, Gao, Lixiong, Hu, Huihui, He, Qing, Jin, Haiying, Li, Zhaohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468448/
https://www.ncbi.nlm.nih.gov/pubmed/36110318
http://dx.doi.org/10.3389/fbioe.2022.989099
_version_ 1784788414086774784
author Ye, Zi
Huang, Yang
Li, Jinglan
Ma, Tianju
Gao, Lixiong
Hu, Huihui
He, Qing
Jin, Haiying
Li, Zhaohui
author_facet Ye, Zi
Huang, Yang
Li, Jinglan
Ma, Tianju
Gao, Lixiong
Hu, Huihui
He, Qing
Jin, Haiying
Li, Zhaohui
author_sort Ye, Zi
collection PubMed
description Posterior capsule opacification (PCO) is one of the most frequent late-onset complications after cataract surgery. Several kinds of drug-eluting intraocular lenses (IOL) were designed for sustainable drug release to suppress ocular inflammation, the proliferation of lens epithelial cells (LECs) and the development of PCO after cataract surgery. Despite previous advances in this field, the drug-loaded IOLs were limited in ocular toxicity, insufficient drug-loading capacity, and short release time. To prevent PCO and to address these drawbacks, a novel drug-loaded IOL (Rapa@Ti(3)C(2)-IOL), prepared from two-dimensional ultrathin Ti(3)C(2) MXene nanosheets and rapamycin (Rapa), was fabricated with a two-step spin coating method in this study. Rapa@Ti(3)C(2) was prepared via electrostatic self-assembly of Ti(3)C(2) and Rapa, with a loading capacity of Rapa at 92%. Ti(3)C(2) was used as a drug delivery reservoir of Rapa. Rapa@Ti(3)C(2)-IOL was designed to have the synergistic photothermal and near infrared (NIR)-controllable drug release property. As a result, Rapa@Ti(3)C(2)-IOL exhibited the advantages of simple preparation, high light transmittance, excellent photothermal conversion capacity, and NIR-controllable drug release behavior. The Rapa@Ti(3)C(2) coating effectively eliminated the LECs around Rapa@Ti(3)C(2)-IOL under a mild 808-nm NIR laser irradiation (1.0 W/cm(−2)). Moreover, NIR-controllable Rapa release inhibited the migration of LECs and suppressed the inflammatory response after photothermal therapy in vitro. Then, Rapa@Ti(3)C(2)-IOL was implanted into chinchilla rabbit eyes, and the effectiveness and biocompatibility to prevent PCO were evaluated for 4 weeks. The Rapa@Ti(3)C(2)-IOL implant exhibited excellent PCO prevention ability with the assistance of NIR irradiation and no obvious pathological damage was observed in surrounding healthy tissues. In summary, the present study offers a promising strategy for preventing PCO via ultrathin Ti(3)C(2) MXene nanosheet-based IOLs with synergistic photothermal and NIR-controllable Rapa release properties.
format Online
Article
Text
id pubmed-9468448
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94684482022-09-14 Two-dimensional ultrathin Ti(3)C(2) MXene nanosheets coated intraocular lens for synergistic photothermal and NIR-controllable rapamycin releasing therapy against posterior capsule opacification Ye, Zi Huang, Yang Li, Jinglan Ma, Tianju Gao, Lixiong Hu, Huihui He, Qing Jin, Haiying Li, Zhaohui Front Bioeng Biotechnol Bioengineering and Biotechnology Posterior capsule opacification (PCO) is one of the most frequent late-onset complications after cataract surgery. Several kinds of drug-eluting intraocular lenses (IOL) were designed for sustainable drug release to suppress ocular inflammation, the proliferation of lens epithelial cells (LECs) and the development of PCO after cataract surgery. Despite previous advances in this field, the drug-loaded IOLs were limited in ocular toxicity, insufficient drug-loading capacity, and short release time. To prevent PCO and to address these drawbacks, a novel drug-loaded IOL (Rapa@Ti(3)C(2)-IOL), prepared from two-dimensional ultrathin Ti(3)C(2) MXene nanosheets and rapamycin (Rapa), was fabricated with a two-step spin coating method in this study. Rapa@Ti(3)C(2) was prepared via electrostatic self-assembly of Ti(3)C(2) and Rapa, with a loading capacity of Rapa at 92%. Ti(3)C(2) was used as a drug delivery reservoir of Rapa. Rapa@Ti(3)C(2)-IOL was designed to have the synergistic photothermal and near infrared (NIR)-controllable drug release property. As a result, Rapa@Ti(3)C(2)-IOL exhibited the advantages of simple preparation, high light transmittance, excellent photothermal conversion capacity, and NIR-controllable drug release behavior. The Rapa@Ti(3)C(2) coating effectively eliminated the LECs around Rapa@Ti(3)C(2)-IOL under a mild 808-nm NIR laser irradiation (1.0 W/cm(−2)). Moreover, NIR-controllable Rapa release inhibited the migration of LECs and suppressed the inflammatory response after photothermal therapy in vitro. Then, Rapa@Ti(3)C(2)-IOL was implanted into chinchilla rabbit eyes, and the effectiveness and biocompatibility to prevent PCO were evaluated for 4 weeks. The Rapa@Ti(3)C(2)-IOL implant exhibited excellent PCO prevention ability with the assistance of NIR irradiation and no obvious pathological damage was observed in surrounding healthy tissues. In summary, the present study offers a promising strategy for preventing PCO via ultrathin Ti(3)C(2) MXene nanosheet-based IOLs with synergistic photothermal and NIR-controllable Rapa release properties. Frontiers Media S.A. 2022-08-30 /pmc/articles/PMC9468448/ /pubmed/36110318 http://dx.doi.org/10.3389/fbioe.2022.989099 Text en Copyright © 2022 Ye, Huang, Li, Ma, Gao, Hu, He, Jin and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Bioengineering and Biotechnology
Ye, Zi
Huang, Yang
Li, Jinglan
Ma, Tianju
Gao, Lixiong
Hu, Huihui
He, Qing
Jin, Haiying
Li, Zhaohui
Two-dimensional ultrathin Ti(3)C(2) MXene nanosheets coated intraocular lens for synergistic photothermal and NIR-controllable rapamycin releasing therapy against posterior capsule opacification
title Two-dimensional ultrathin Ti(3)C(2) MXene nanosheets coated intraocular lens for synergistic photothermal and NIR-controllable rapamycin releasing therapy against posterior capsule opacification
title_full Two-dimensional ultrathin Ti(3)C(2) MXene nanosheets coated intraocular lens for synergistic photothermal and NIR-controllable rapamycin releasing therapy against posterior capsule opacification
title_fullStr Two-dimensional ultrathin Ti(3)C(2) MXene nanosheets coated intraocular lens for synergistic photothermal and NIR-controllable rapamycin releasing therapy against posterior capsule opacification
title_full_unstemmed Two-dimensional ultrathin Ti(3)C(2) MXene nanosheets coated intraocular lens for synergistic photothermal and NIR-controllable rapamycin releasing therapy against posterior capsule opacification
title_short Two-dimensional ultrathin Ti(3)C(2) MXene nanosheets coated intraocular lens for synergistic photothermal and NIR-controllable rapamycin releasing therapy against posterior capsule opacification
title_sort two-dimensional ultrathin ti(3)c(2) mxene nanosheets coated intraocular lens for synergistic photothermal and nir-controllable rapamycin releasing therapy against posterior capsule opacification
topic Bioengineering and Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468448/
https://www.ncbi.nlm.nih.gov/pubmed/36110318
http://dx.doi.org/10.3389/fbioe.2022.989099
work_keys_str_mv AT yezi twodimensionalultrathinti3c2mxenenanosheetscoatedintraocularlensforsynergisticphotothermalandnircontrollablerapamycinreleasingtherapyagainstposteriorcapsuleopacification
AT huangyang twodimensionalultrathinti3c2mxenenanosheetscoatedintraocularlensforsynergisticphotothermalandnircontrollablerapamycinreleasingtherapyagainstposteriorcapsuleopacification
AT lijinglan twodimensionalultrathinti3c2mxenenanosheetscoatedintraocularlensforsynergisticphotothermalandnircontrollablerapamycinreleasingtherapyagainstposteriorcapsuleopacification
AT matianju twodimensionalultrathinti3c2mxenenanosheetscoatedintraocularlensforsynergisticphotothermalandnircontrollablerapamycinreleasingtherapyagainstposteriorcapsuleopacification
AT gaolixiong twodimensionalultrathinti3c2mxenenanosheetscoatedintraocularlensforsynergisticphotothermalandnircontrollablerapamycinreleasingtherapyagainstposteriorcapsuleopacification
AT huhuihui twodimensionalultrathinti3c2mxenenanosheetscoatedintraocularlensforsynergisticphotothermalandnircontrollablerapamycinreleasingtherapyagainstposteriorcapsuleopacification
AT heqing twodimensionalultrathinti3c2mxenenanosheetscoatedintraocularlensforsynergisticphotothermalandnircontrollablerapamycinreleasingtherapyagainstposteriorcapsuleopacification
AT jinhaiying twodimensionalultrathinti3c2mxenenanosheetscoatedintraocularlensforsynergisticphotothermalandnircontrollablerapamycinreleasingtherapyagainstposteriorcapsuleopacification
AT lizhaohui twodimensionalultrathinti3c2mxenenanosheetscoatedintraocularlensforsynergisticphotothermalandnircontrollablerapamycinreleasingtherapyagainstposteriorcapsuleopacification